From Name

From Email

To Name

To Email

Message

Study data support higher-dose lenvatinib for radioactive iodine-refractory thyroid cancer

from Healio

Study data support higher-dose lenvatinib for radioactive iodine-refractory thyroid cancer Healio An 18 milligram starting dose of the oral tyrosine kinase inhibitor lenvatinib did not meet the noninferiority requirement compared with the approved, 24 milligram starting dose for adults with radioactive iodine-refractory thyroid cancer, data show. READ MORE

more